Frequently Asked Questions
The market is segmented based on Global Methotrexate Injection Market, By Disease Type (Leukaemia, Psoriasis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Vasculitis, Reactive Arthritis, Localised Scleroderma, Uveitis, Lupus (SLE), Juvenile Dermatomyositis, Others), Drug Type (Branded, Generics), Population (Adults, Paediatric, Others), Route of Administration (Intramuscular, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Methotrexate Injection Market size was valued at USD 527.52 USD Million in 2022.
The Global Methotrexate Injection Market is projected to grow at a CAGR of 2.6% during the forecast period of 2023 to 2030.
The major players operating in the market include Cumberland Pharmaceuticals , Medexus Pharmaceuticals , Teva Pharmaceutical Industries , LUPIN, Hikma Pharmaceuticals PLC, Alkem Labs , PRAGMA therapeutics, Sandoz AG, GlaxoSmithKline Plc., Par Pharmaceutical , Amneal Pharmaceutical , Mylan N.V., Sun Pharmaceutical Industries , Dr. Reddy's Laboratories, Aurobindo Pharma Limited, Perrigo Company plc, Akron , Cosette Pharmaceuticals.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa.
